Catalyst Calendar

Tue, Sep 29, 2026

1 updates

7:00 AM

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Poster presentation at ESMO Congress 2026 will highlight findings from trial of zoci in combination with atezolizumab with and without carboplatin Data adds to body of evidence supporting zoci as a potential backbone antibody-drug conjugate in first-line combination regimens for ES-SCLC Investor

Presentation / Abstract • Phase 1ESMO poster presentation Mon, Oct 26, 2026, 12:00 PM CESTzailaboratory.com

Mon, Aug 17, 2026

1 updates

ZLAB

6:00 AM

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM First Phase 3 study to show

Trial Results • Phase 3Topline results Mon, Aug 17, 2026zailaboratory.com

Thu, Aug 6, 2026

1 updates

ZLAB

6:30 AM

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

The Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with significant pipeline catalysts expected in the second half of 2026 Global Phase 1 data for zocilurtatug pelitecan (zoci) in combination with a PD-L1 inhibitor in first-line SCLC

Presentation / Abstract • Phase 1zailaboratory.com

Mon, Aug 3, 2026

1 updates

ZLAB

7:00 AM

U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

- NECs are aggressive malignancies with poor prognoses and limited treatment options, representing significant unmet patient need - U.S. FDA Orphan Drug Designation (ODD) follows receipt of ODD for zoci in pulmonary NECs from the European Medicines Agency, reinforcing zoci’s first-in-class

zailaboratory.com

Wed, Jul 22, 2026

1 updates

ZLAB

7:30 AM

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

- Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT) SHANGHAI & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 22, 2026-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its second quarter 2026 financial results and provide

zailaboratory.com